NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Up 0.4% – Here’s What Happened

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)’s stock price shot up 0.4% during mid-day trading on Monday . The stock traded as high as $0.4990 and last traded at $0.4670. 452,053 shares changed hands during mid-day trading, an increase of 52% from the average daily volume of 297,059 shares. The stock had previously closed at $0.4652.

Analyst Ratings Changes

A number of research firms recently commented on NRSN. D. Boral Capital reiterated a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a report on Wednesday, April 8th. Weiss Ratings lowered NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

NeuroSense Therapeutics Stock Performance

The firm has a fifty day simple moving average of $0.71 and a 200-day simple moving average of $0.80. The firm has a market cap of $20.46 million, a price-to-earnings ratio of -1.00 and a beta of 1.62.

Insider Activity

In related news, CEO Alon Ben-Noon bought 250,000 shares of NeuroSense Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The stock was acquired at an average price of $0.80 per share, with a total value of $200,000.00. Following the acquisition, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. This represents a 5.84% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Or Eisenberg purchased 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was bought at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the purchase, the chief financial officer owned 1,504,050 shares in the company, valued at $1,203,240. The trade was a 19.94% increase in their position. The SEC filing for this purchase provides additional information. 27.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On NeuroSense Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Yorkville Advisors Global LP bought a new stake in shares of NeuroSense Therapeutics during the fourth quarter worth approximately $77,000. Squarepoint Ops LLC increased its stake in shares of NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares during the period. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics during the second quarter worth approximately $54,000. Finally, Two Sigma Investments LP acquired a new stake in NeuroSense Therapeutics during the 3rd quarter worth approximately $26,000. 1.04% of the stock is currently owned by institutional investors and hedge funds.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.